Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282186 · ClinicalTrials.gov registry record · NA
What the Nose Knows: Hedonic Capacity, Psychosocial Interventions and Outcomes in Schizophrenia
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 134
- Enrollment target
NCT05282186: Completed NA study, sponsored by Beth Israel Deaconess Medical Center.
NCT05282186 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 134 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05282186, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 134 participants
- Enrollment target
Study Summary
This project proposes to conduct the first study of the predictive utility of olfactory hedonic measurement for targeted psychosocial rehabilitation in schizophrenia. The information gathered from the project is of considerable public health relevance, in that, through simple, reliable olfactory assessment, it will provide knowledge about which individuals are most likely to benefit from these psychosocial interventions. Such information is crucial for tailoring existing interventions and developing new approaches to optimize outcomes in schizophrenia.
Primary Outcome
Measure of ability to engage socially in community settings
Interventions
- BEHAVIORAL Cognitive Enhancement Therapy
- BEHAVIORAL Social Skills Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2022-09-02 |
| Est. Completion | 2025-05-31 |
| Phase | NA |
What the finished NCT05282186 record still lists
NCT05282186 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Cognitive Enhancement Therapy is the first listed.
NCT05282186 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05282186 about?
NCT05282186 is a clinical study titled "What the Nose Knows: Hedonic Capacity, Psychosocial Interventions and Outcomes in Schizophrenia". This project proposes to conduct the first study of the predictive utility of olfactory hedonic measurement for targeted psychosocial rehabilitation in schizophrenia. The information gathered from the project is of considerable public health relevance, in that, through simple, reliable olfactory ass...
What is the current status of trial NCT05282186?
This trial is currently completed. It is a NA study. The enrollment target is 134 participants. The study started on 2022-09-02. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT05282186?
The interventions under investigation include: Cognitive Enhancement Therapy (BEHAVIORAL), Social Skills Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05282186?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05282186's enrollment target sits among peer trials
134 728th of 2000 higher than 1,272 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI